Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD9150 + durvalumab + gemcitabine + carboplatin
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**AZD9150 + durvalumab + gemcitabine + carboplatin** is an investigational combination regimen studied in patients with advanced solid tumors, including non-small cell lung cancer. - **AZD9150 (danvatirsen)** is an antisense oligonucleotide targeting STAT3, inhibiting its expression and reducing downstream oncogenic signaling. - **Durvalumab (MEDI4736)** is a monoclonal antibody and checkpoint inhibitor that blocks PD-L1, enhancing T cell-mediated immune responses against tumors. - **Gemcitabine** is a nucleoside analog antimetabolite that interferes with DNA synthesis, leading to apoptosis in rapidly dividing cells. - **Carboplatin** is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis in cancer cells. This regimen is being evaluated for its safety, tolerability, pharmacokinetics, and anti-tumor activity in phase Ib/II clinical trials[1][3][4][5][7][8].
- Other names
- danvatirsen + durvalumab + gemcitabine + carboplatin
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on AZD9150 + durvalumab + gemcitabine + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD9150 + durvalumab + gemcitabine + carboplatin.